COPD
5 videos · updated daily
44:17 AI Imaging Biomarkers in Drug Development: VIDA's Susan Wood
Susan Wood, PhD, President and CEO of VIDA Intelligence, discusses on Progress, Potential, and Possibilities how AI-based quantitative CT imaging can turn lung scans into biomarkers for diagnosing pulmonary disease and for clinical drug development.
5:51 AERIFY Phase 3 Results for Itepekimab in COPD
Klaus F. Rabe, MD, PhD, discusses mixed phase 3 AERIFY results for itepekimab in former smokers with COPD at ATS 2026, saying in May 2026 that inconsistent results likely mean more data before regulatory approval.
1:01:27 Evidence Beyond FEV1 for Respiratory Biologics
A Lindus Health panel discusses designing Phase 3b, Phase 4 and prospective real-world evidence studies for asthma and COPD biologics that meet payor and HTA needs, including remote spirometry and digital biomarkers.
1:00:00 Respiratory Drug Development: Comprehensive Strategies to Improve Data Quality
A Clario webinar on strategies to improve data quality in respiratory drug development trials.
1:52:05 Late-Breaking Clinical Trials in Pulmonary Medicine
An American Thoracic Society 2020 session chaired by MeiLan K. Han, MD, presents late-breaking trials including ETHOS in COPD, the phase 2 WILLOW study of brensocatib in bronchiectasis and INCREASE of inhaled treprostinil.